Who owns Xeris Biopharma Holdings, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of XERS from SEC Form 13F filings across 240 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 240 institutions disclosed 108.2M shares of Xeris Biopharma Holdings, Inc. worth $857.0M — about 62.6% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
240
13F holders
$857.0M
value, 2026 filers
62.6%
of shares outstanding (108.2M sh)
43
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of XERS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 14.5M | $115.0M | 0.0% | 8.4% | +12.2% |
| 2 | D. E. Shaw & Co., Inc. | 7.8M | $61.8M | 0.0% | 4.5% | +0.2% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLCNEW | 7.3M | $58.1M | 0.0% | 4.2% | new |
| 4 | STATE STREET CORP | 4.8M | $38.2M | 0.0% | 2.8% | +3.5% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 4.7M | $37.4M | 0.0% | 2.7% | +10.0% |
| 6 | Nuveen, LLC | 4.4M | $34.7M | 0.0% | 2.5% | +50.4% |
| 7 | Rosalind Advisors, Inc. | 2.9M | $23.0M | 8.6% | 1.7% | -10.0% |
| 8 | Qube Research & Technologies Ltd | 2.9M | $22.9M | 0.0% | 1.7% | -29.7% |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLCNEW | 2.6M | $20.8M | 0.0% | 1.5% | new |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 2.4M | $18.7M | 0.0% | 1.4% | +8.9% |
| 11 | MORGAN STANLEY | 2.3M | $18.5M | 0.0% | 1.4% | -9.2% |
| 12 | Legal & General Group Plc | 2.0M | $15.9M | 0.0% | 1.2% | +5.5% |
| 13 | ARMISTICE CAPITAL, LLC | 2.0M | $15.5M | 0.2% | 1.1% | +2.6% |
| 14 | TWO SIGMA INVESTMENTS, LP | 1.9M | $14.9M | 0.0% | 1.1% | -2.0% |
| 15 | Parkman Healthcare Partners LLC | 1.8M | $14.3M | 1.5% | 1% | +5.0% |
| 16 | ALGERT GLOBAL LLC | 1.7M | $13.8M | 0.2% | 1% | +50.6% |
| 17 | NORTHERN TRUST CORP | 1.6M | $12.7M | 0.0% | 0.9% | +10.6% |
| 18 | GOLDMAN SACHS GROUP INC | 1.6M | $12.6M | 0.0% | 0.9% | -1.2% |
| 19 | AQR CAPITAL MANAGEMENT LLC | 1.5M | $12.2M | 0.0% | 0.9% | +10.5% |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.5M | $11.8M | 0.0% | 0.9% | +9.8% |
| 21 | FEDERATED HERMES, INC. | 1.4M | $11.4M | 0.0% | 0.8% | +67.4% |
| 22 | BANK OF AMERICA CORP /DE/ | 1.4M | $11.1M | 0.0% | 0.8% | +59.8% |
| 23 | UBS Group AG | 1.3M | $10.3M | 0.0% | 0.8% | -21.0% |
| 24 | Ishara Investments LP | 1.2M | $9.7M | 7.2% | 0.7% | +20.0% |
| 25 | VANGUARD FIDUCIARY TRUST CONEW | 1.2M | $9.7M | 0.0% | 0.7% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.